IPSEN (OTCMKTS:IPSEY) Share Price Crosses Above 200 Day Moving Average – What’s Next?

Posted by ABMN Staff on Feb 5th, 2026

IPSEN (OTCMKTS:IPSEY – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $35.07 and traded as high as $40.41. IPSEN shares last traded at $40.41, with a volume of 657 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. UBS Group lowered IPSEN from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Monday, November 3rd. Finally, BNP Paribas Exane cut IPSEN to an “underperform” rating in a research report on Wednesday, November 26th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, IPSEN has an average rating of “Hold”.

Check Out Our Latest Stock Analysis on IPSEY

IPSEN Price Performance

The business’s 50-day simple moving average is $37.04 and its 200-day simple moving average is $35.07.

About IPSEN

(Get Free Report)

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).